My Companies
Notification
Account
Log Out
Login
AstraZeneca Pharma India received CDSCO approval to import and market Fasenra (benralizumab) for an additional indication: Hypereosinophilic Syndrome in patients aged 12 years and older, expanding the drug's label in India.
No events have occurred recently